Document 3eg2JXd4eJKQZYYNMGMvdZ18J

FC Core Team 2004 - 2005 Project / Process P riorities Client-Attorney Priveleged Work Product: Do not copy or distribute S tra te g y /B C Y 's P ro je c t & P ro c e s s e s C om m and the science: exposure, analytical, fate, e ffe c ts , hum an health and e cological D e ve lo p and m aintain internal 3M analytical capability - te lo m e rs and E C F ch e m istrie s D e ve lo p stra te g y fo r external scie n ce w ith re s p e c t to te lo m e rs and E C F ch e m istrie s U nderstand T F A risk a sse ssm e n t w ork D e v e lo p a nd im p le m e n t a 3M P u b lica tio n P lan: R e s e a rc h to b e p u b lis h e d as c o m p le te d in o p e n s c ie n tific lite ra tu re - health re s e a rc h D e v e lo p a nd im p le m e n t a 3M P u b lica tio n P lan: R e s e a rc h to b e p u b lis h e d as c o m p le te d in o p e n s c ie n tific lite ra tu re - e n viro n m e n ta l. C reate a p ro ce ss to track global FC related w ork ou tsid e o f 3M (P ublic universities, g o ve rn m en t institutes, etc.,including literature and funding). D e ve lo p p ro c e s s to m onitor scie n tific literature fo r new data w ith re s p e c t to health e ffe c ts and environm ental issu e s T ra c k d e v e lo p m e n ts o f b io m o n ito rin g b y C e n te rs fo r D is e a s e C o n tro l ( C D C ). If necessary, hold w o rksh o p fo r third party s p o ke sp e rso n s and include preparation fo r S cie n ce A d viso ry Panel public m e e tin g s R e visit 3M S c ie n tific A d v is o ry B oard: D e fin e role, if any, o f 3M S A B in th e E P A P F O A risk a s s e s s m e n t and P F O S IR IS p ro c e s s e s . D evelop strategy to p re se n t to E PA S A B on P F O A risk asse ssm e n t, include industry team . R e e sta b lish international regu la to ry-scie n tific-le g a l-p ub lic a ffa irs in fra structure-identify re so u rce s, re sp o n sib ilitie s and rela tio n sh ip s to US C ore Team . T ra ck a g e n d a s for, b e aw are o f and p a rtic ip a te in s c ie n c e a nd re g u la to ry c o n fe re n c e s . D evelop strategy to build stronger (International) O U S scie n ce representation at the R esearch S cie n ce Level D e velop strategy to build stro n g e r (International) O U S scie n ce representation at the S cie n ce P olicy Level D e ve lo p and im p le m e n t a program to u n derstand th e to xico lo g y and environm ental m e ch a n ism s fo r su p p o rt o f th e P FO S , P FO A , R eview the adequacy o f the e p id e m io lo g y data and a d d re ss any gaps. E valuate P F O A p re c u rs o rs in o th e r p ro d u c ts , if any. R eview the adequacy o f the biom onitoring data and a d d re ss any gaps. Achieve neutral to positive regulatory agency outcom es: findings and actions Develop an Asian strategy for PFOS regulation, Japan being first. Develop an Asian strategy for PFOA regulation. Japan being first. Develop an EU strategy for PFOS science policy Develop an EU strategy for PFO A science policy Ensure sound science and appropriate risk management at EU level by staying engaged with UK-DEFRA Risk Reduction Strategy Canada - PFOS Environmental A ssessm ent: Continue to maintain good relations with Environment Canada through regular contacts and strive to ensure that the final assessm ent - and any actions based thereon - are accurate and fair. OECD: Continue to monitor OECD for further regulatory developm ents. United Nations Environmental Programme (UNEP): Continue to monitor UNEP activities for further PFOS/PFOA-related Track Activities o f S w eden C hem icals Inspectorate. Ensure sound science and appropriate risk m anagem ent by staying engaged with Review historical use o f IR IS reviews by international, national, state and local authorities. Look at related cases (e.g. PCB's) and Monitor (US) federal and state legislative and regulatory activities related to FC's. Biom onitoring bill in CA, etc. Prepare and subm it final perfluorooctanyl phase-out summary to EPA when 3M inventories are substantially expired. Establish and strengthen dialogue with EPA's ORD (Dr. Preuss) and managem ent (C. Auer. S. Johnson) and other parties outside EPA who will be influential in PFO S and PFO A risk a ssessm ent p ro ce sse s and other science policy m atters affecting FC's. US political strategy: U pdate the political strategy docum ent and key contacts listing and im plem ent agreed plan. Satisfy C8 regulatory commitments Satisfy 3M letter o f Intent (LOI) comm itm ents Satisfy Dyneon letter o f Intent (LOI) comm itm ents Society o f Plastics Industry (SPI): W ork successfully with FMG and SPI to com plete ECA negotiations and im plem ent LOI/ECA co m m itm e n ts. S upport A ssociation o f Plastics Manufacturers in Europe (APM E) toxicology and environmental study program s. S et up internal m anagem ent review for Decatur site m onitoring issues. S et up internal m anagem ent review for G endorf site m onitoring issues. S et up internal m anagem ent review for Cottage G rove site m onitoring issues. Satisfy MOU Process - 3M Site Monitoring - PFOA Antwerp groundwater/site assessm ent: Complete risk assessm ent. Cottage Grove-Drinking W ater (MN Dept, o f Health): D eterm ine m onitoring and p rocess control requirem ents. C om plete 8(e) S e lf Disclosure and settlem ent Phase IV audit. Monitor and prioritize external trends and organizations affecting FC's Monitor and understand future direction (globally) of NGO 's and partnerships. Effective communication. Media attention to PFOA Risk Assessm ent/SAB Review: W ork with industry group to take the lead on defense o f PFO A and science. Maintain preparedness in order to respond to PFO A m edia coverage o f risk assessm ent. Maintain talking points for ECA/LOI and other US regulatory activities. Maintain 3M Sumitomo talking points for PFOA / SAB. D evelop a m essage testing m echanism for talking points particularly in Europe Maintain talking points: C4 chemistry. Maintain talking points: 8(e) voluntary com pliance audit. Maintain talking points: Decatur litigation. Assure FC Enterprise Risk Management organizational health. Conduct a resource review (current and prospective) for ongoing issue management needs. C4 Regulatory and Product Stewardship Strategy Maintain dialogue with EPA and international regulators on C4 chemistry. consent orders at the earliest possible time. Include EPA / NTP class study activity. Catalog all current 3M C4 product applications. P rocess and control plan needed. Review the adequacy of the C4 polymer degradation data and address any gaps. Evaluate scenarios for full commercialization o f PFBS (m odelling project) Develop a reference dose for C4 to determine if environmental/biomonitoring need to be done. Im prove review process o f all C 4 com m ercialization e ffo rts in 3M. Continue phaseout trajectory (C8 use/emission/exposure reduction) Prepare a summary o f existing perfluorooctanyl inventories across 3M's business units and establish tim etables for consum ption or use o f inventories. Review PFOS exposure assessm ents and related information. Develop strategy about monitoring o f possible source areas, based on existing PFOS exposure assessm ents and modelling.